Biodesix, Inc.

NASDAQ:BDSX

Medical - Diagnostics & Research

Healthcare
$8.40 +13.40%

+$2.04 today

Market cap
$68.38M
Beta
0.59
P/E (TTM)
-5.2
EPS (TTM)
-$3.31
52W Low $5.00High $20.21

Volume 0.17M

Average 0.06M

BDSX Debt Repayment

Cash used to repay borrowings during the period.

Biodesix, Inc.NASDAQ: BDSX

Debt Repayment · Q1 FY2026 · quarter ended Mar 2026

Debt repayment dips below year-ago levels

Q1 FY2026 debt repayment of $5K (cash outflow) fell 28.6% year over year, behind the +22340.0% change in trailing-twelve-month debt repayment. Over 3 fiscal years it compounded at -15.4% a year.

Context

  • Debt repayment amounted to 11.3% of revenue in FY2025, up 11.2 pp from a year earlier.
  • Debt repayment increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -28.6% toward the trailing-twelve-month pace of +22340.0%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$5K-120.0% QoQ
Last fiscal yearDec 2025
$9.98M+19666.7% YoY
LTMMar 2026
$10.01M+22340.0% YoY
Debt Repayment past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-28.6%——
1 year+19666.7%——
3-year CAGR-15.4%——
5-year CAGR——
10-year CAGR——

Debt Repayment history

USD · from the cash flow

Latest · FY2025
9.98M USD
Year-over-year change
+19666.7%

Debt Repayment vs competitors

How BDSX compares with its peers on the latest reported figures

  • BDSX's LTM Mar 2026 debt repayment of $10.01M is the 2nd largest of the 5 companies compared; the peer median is $0.
  • Its year-over-year change of +22340.0% is the highest of 4, against a peer median of +100.0%.
  • Debt repayment amounts to 10.4% of revenue for BDSX, versus a peer median of 0.0%.
BDSX Competitors Peer median
Debt Repayment for BDSX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PDSBPDS Biotechnology CorporationLTM Mar 2026$25.17M +299.1%——
BDSXBiodesix, Inc.LTM Mar 2026$10.01M +22340.0%-15.4%10.4%
OKUROnKure Therapeutics, Inc.LTM Mar 2026$0 ———
XLOXilio Therapeutics, Inc.LTM Mar 2026$0 -100.0%—0.0%
INMBINmune Bio, Inc.LTM Mar 2026$0 +100.0%——
Peer median (excluding BDSX) $0+100.0%—0.0%

Competitors are the stored peer set for BDSX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(43.16M)(65.45M)(52.15M)(42.93M)(35.27M)
Depreciation & Amortization3.18M5.84M5.51M5.46M5.6M
Deferred Income Tax(2.11M)0000
Stock-Based Compensation4.94M5.96M5.37M6.64M4.14M
Change in Working Capital4.59M(4.34M)11.3M(21.67M)334K
Accounts Receivables11.45M(1.5M)(4.72M)(1.81M)(531K)
Inventory7.43M906K166K22K0
Accounts Payables(7.43M)(773K)513K1.64M0
Other Working Capital(6.86M)(2.98M)15.34M(21.52M)865K
Other Non-Cash Items4.33M13.01M7.09M3.86M1.92M
Operating Cash Flow(28.22M)(44.97M)(22.87M)(48.65M)(23.27M)
Capital Expenditures(2.55M)(3.53M)(23.06M)(3.23M)(403K)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities(306K)(236K)(143K)(210K)(144K)
Investing Cash Flow(2.55M)(3.53M)(23.06M)(3.44M)(403K)
Debt Repayment(15.35M)16.5M9.95M(51K)9.98M
Common Stock Issued16.34M59.54M28.13M55.63M7.82M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities269K(17.15M)(8.95M)(3.52M)(1.38M)
Financing Cash Flow1.26M58.88M29.13M52.05M16.42M
Effect of Forex Changes00000
Net Change in Cash(29.51M)10.38M(16.8M)(39K)(7.26M)
Free Cash Flow(30.77M)(48.51M)(45.93M)(51.88M)(23.67M)

Biodesix, Inc.

NASDAQ:BDSX

Intrinsic Alpha fair value

Locked

Current Price

$8.40

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.